Secukinumab approved for psoriatic arthritis and ankylosing spondylitis

Secukinumab approved for psoriatic arthritis and ankylosing spondylitis

Novartis announced January 15 that the FDA has approved secukinumab (Cosentyx, Novartis) for psoriatic arthritis (PsA) and active ankylosing spondylitis. The announcement comes a year after the FDA's approval for secukinumab for treatment of adults

(Visited 1 times, 1 visits today)
2
Like
Save

Comments

Comments are disabled for this post.